Menu
Recruiting NCT03778944

Enhancing Renal Graft Function During Donor Anesthesia

No phase Interventional Renal Failure Chronic Transplant;Failure,Kidney Anesthesia

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Mannitol infusion, Dopamine infusion, Adequate hydration.
Who it may be relevant to
Registry conditions: Renal Failure Chronic, Transplant;Failure,Kidney, Anesthesia. Basic parameters: 18 years — 60 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Egypt
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

Renal Graft Functional Enhancement During Donor Anesthesia: A Comparative Study of 3 Modalities

Overview

Renal transplantation is now recognized as the treatment of choice for patients with end-stage renal disease. An optimum anesthetic regimen should enhance the function and perfusion of the transplanted kidney. The aim of this study is to assess \& compare the effectiveness of 3 different modalities in this respect: Mannitol, Dopamine and adequate hydration.

Interventions

  • Procedure Mannitol infusion
    Infusion of Mannitol 20% at a dose of 0.5 mg/kg to the renal graft donor after induction of anesthesia over 15 minutes.
  • Procedure Dopamine infusion
    Infusion of Dopamine at a dose of 4 microg/kg/min to the renal graft donor after induction of anesthesia till ligation of the renal artery.
  • Procedure Adequate hydration
    Infusion of Ringer Acetate at a rate of 15 ml/kg/hr to the renal graft donor after induction of anesthesia till ligation of the renal artery.

Primary outcome measures

  • Post-operative creatinine clearance [Time frame: 7 days]

Eligibility criteria

Inclusion criteria

  • end-stage renal disease, for living-donor kidney transplantation

Exclusion criteria

  • severe cardiac or hepatic dysfunction
  • coagulopathy

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Single blind
Primary purpose
Supportive care

Study locations

Egypt · 1 center
  • Kasr Al-Ainy Hospital, Cairo University — Cairo

Identifiers

NCT: NCT03778944 · RGFEDDA

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗